Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
The study was conducted at 15 centers (2 of which did not enroll any patients). A total of 79 hemodialysis patients were assigned randomly to one of two treatment sequences.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patient had received hemodialysis three times per week for 3 months or longer;
patients were maintained on sevelamer hydrochloride as their primary phosphate binder with a total daily dose of ≤ 13.6 g with serum phosphorus concentrations at the last two measurements between 3.0 and 6.5 mg/dL, the most recent iPTH ≤ 600 pg/mL and the most recent serum calcium within the normal range.
You may not be if
if patient had active bowel obstruction, dysphagia, swallowing disorders, or severe gastrointestinal motility disorders;
active ethanol or drug abuse (excluding tobacco);
need for antidysrhythmic or antiseizure medications used to control these conditions;
poorly controlled diabetes mellitus or hypertension;
active vasculitis;
active malignancy other than basal-cell carcinoma;
HIV infection; or
any clinically significant unstable medical condition as judge by the Investigator.
